NASDAQ:MESO - Mesoblast Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.52 +0.03 (+0.55 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$5.49
Today's Range$5.45 - $5.67
52-Week Range$3.35 - $8.78
Volume66,871 shs
Average Volume54,858 shs
Market Capitalization$519.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.34 million
Book Value$5.80 per share

Profitability

Net Income$-35,290,000.00
Net Margins-528.80%

Miscellaneous

EmployeesN/A
Market Cap$519.82 million
Next Earnings Date5/30/2019 (Estimated)
OptionableOptionable

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) posted its earnings results on Wednesday, February, 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The firm earned $1.87 million during the quarter, compared to analysts' expectations of $6.36 million. Mesoblast had a negative return on equity of 15.98% and a negative net margin of 528.80%. View Mesoblast's Earnings History.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Thursday, May 30th 2019. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

4 Wall Street analysts have issued 1 year price targets for Mesoblast's shares. Their forecasts range from $6.50 to $23.00. On average, they expect Mesoblast's share price to reach $15.1250 in the next twelve months. This suggests a possible upside of 174.0% from the stock's current price. View Analyst Price Targets for Mesoblast.

What is the consensus analysts' recommendation for Mesoblast?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:
  • 1. Maxim Group analysts commented, "Mesoblast announced that the FDA has agreed to a rolling review of the BLA for Remestemcel-L in pediatric steroid-refractory aGvHD. The company intends to begin the submission process soon." (4/16/2019)
  • 2. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (4/3/2019)
  • 3. HC Wainwright analysts commented, "We maintain our Buy rating of MESO with a 12-month price target of $6.50 per diluted share. We derive our price target based on an NPV analysis of projected product revenues through FY2030. We assume a 12.2% discount rate, formulated by our calculation of Mesoblast’s weighted average cost of capital, and 3% terminal growth rate. We derive an NPV of $1.1B and add in pro forma net cash of $28.5M to arrive at a 12-month price target of $6.62, which we round to $6.50. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (2/22/2019)

Has Mesoblast been receiving favorable news coverage?

Media headlines about MESO stock have trended somewhat positive on Friday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $5.52.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $519.82 million and generates $17.34 million in revenue each year. The company earns $-35,290,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

What is Mesoblast's official website?

The official website for Mesoblast is http://www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (NASDAQ MESO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel